Growth factor mediated signaling in pancreatic pathogenesis

Cancers

Volumn 3, Issue 1, 2011, Pages 841-871

  Nandy, Debashis ^a   Mukhopadhyay, Debabrata ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Growth factors; Pancreatic carcinoma; Pancreatitis; Signaling

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; GEMCITABINE; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ACUTE PANCREATITIS; ADJUVANT THERAPY; AUTOIMMUNE PANCREATITIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CARCINOGENESIS; CAUSE OF DEATH; CHRONIC PANCREATITIS; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; NONHUMAN; ORGANOGENESIS; PANCREAS CARCINOMA; PANCREAS CYST; PANCREAS DISEASE; PANCREAS SURGERY; PANCREAS TUMOR; PATHOGENESIS; PATHOPHYSIOLOGY; PRECANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION;

EID: 79953721180     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010841     Document Type: Review

References (181)

1. Suckale, J.; Solimena, M. Pancreas islets in metabolic signaling-Focus on the beta-cell. Front. Biosci. 2008, 13, 7156-7171.
2. Le Bras, S.; Miralles, F.; Basmaciogullari, A.; Czernichow, P.; Scharfmann, R. Fibroblast growth factor 2 promotes pancreatic epithelial cell proliferation via functional fibroblast growth factor receptors during embryonic life. Diabetes 1998, 47, 1236-1242.
3. Edlund, H. Pancreatic organogenesis-Developmental mechanisms and implications for therapy. Nat. Rev. Genet. 2002, 3, 524-532.
4. Rawdon, B.B.; Andrew, A. Effects of tri-iodothyronine (t3), insulin, insulin-like growth factor i (IGF-i) and transforming growth factor beta1 (tgfb1) on the proportion of insulin cells in cultured embryonic chick pancreas. Anat. Embryol. 1998, 198, 245-254.
5. Manfroid, I.; Delporte, F.; Baudhuin, A.; Motte, P.; Neumann, C.J.; Voz, M.L.; Martial, J.A.; Peers, B. Reciprocal endoderm-mesoderm interactions mediated by fgf24 and fgf10 govern pancreas development. Development 2007, 134, 4011-4021.
6. Folkman, J.; Watson, K.; Ingber, D.; Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339, 58-61.
7. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27-31.
8. Folkman, J. Seminars in medicine of the beth israel hospital, boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 1995, 333, 1757-1763.
9. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
10. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 1990, 82, 4-6.
11. Fidler, I.J.; Ellis, L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79, 185-188.
12. Ferrara, N.; Heinsohn, H.; Walder, C.E.; Bunting, S.; Thomas, G.R. The regulation of blood vessel growth by vascular endothelial growth factor. Ann. N. Y. Acad. Sci. 1995, 752, 246-256.
13. Ferrara, N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 1995, 36, 127-137.
14. Kolch, W.; Martiny-Baron, G.; Kieser, A.; Marme, D. Regulation of the expression of the vegf/vps and its receptors: Role in tumor angiogenesis. Breast Cancer Res. Treat. 1995, 36, 139-155.
15. Thomas, K.A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 1996, 271, 603-606.
16. Luo, J.; Guo, P.; Matsuda, K.; Truong, N.; Lee, A.; Chun, C.; Cheng, S.Y.; Korc, M. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int. J. Cancer 2001, 92, 361-369.
17. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983-985.
18. Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246, 1306-1309.
19. Shibuya, M. Structure and function of vegf/vegf-receptor system involved in angiogenesis. Cell Struct. Funct. 2001, 26, 25-35.
20. Friess, H.; Cantero, D.; Graber, H.; Tang, W.H.; Guo, X.; Kashiwagi, M.; Zimmermann, A.; Gold, L.; Korc, M.; Buchler, M.W. Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis. Gastroenterology 1997, 113, 904-913.
21. Shibuya, M. Role of vegf-flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res. 1995, 67, 281-316.
22. Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18, 4-25.
23. Houck, K.A.; Ferrara, N.; Winer, J.; Cachianes, G.; Li, B.; Leung, D.W. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of rna. Mol. Endocrinol. 1991, 5, 1806-1814.
24. Tischer, E.; Mitchell, R.; Hartman, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J.C.; Abraham, J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 1991, 266, 11947-11954.
25. Poltorak, Z.; Cohen, T.; Sivan, R.; Kandelis, Y.; Spira, G.; Vlodavsky, I.; Keshet, E.; Neufeld, G. Vegf145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 1997, 272, 7151-7158.
26. Houck, K.A.; Leung, D.W.; Rowland, A.M.; Winer, J.; Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 1992, 267, 26031-26037.
27. Acosta, J.M.; Ledesma, C.L. Gallstone migration as a cause of acute pancreatitis. N. Engl. J. Med. 1974, 290, 484-487.
28. Kieser, A.; Weich, H.A.; Brandner, G.; Marme, D.; Kolch, W. Mutant p53 potentiates protein kinase c induction of vascular endothelial growth factor expression. Oncogene 1994, 9, 963-969.
29. Shweiki, D.; Itin, A.; Soffer, D.; Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
30. Ikeda, E.; Achen, M.G.; Breier, G.; Risau, W. Hypoxia-induced transcriptional activation and increased mrna stability of vascular endothelial growth factor in c6 glioma cells. J. Biol. Chem. 1995, 270, 19761-19766.
31. Mukhopadhyay, D.; Datta, K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin. Cancer Biol. 2004, 14, 123-130.
32. Maeda, K.; Kang, S.M.; Ogawa, M.; Onoda, N.; Sawada, T.; Nakata, B.; Kato, Y.; Chung, Y.S.; Sowa, M. Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int. J. Cancer 1997, 74, 545-550.
33. Gasparini, G.; Toi, M.; Gion, M.; Verderio, P.; Dittadi, R.; Hanatani, M.; Matsubara, I.; Vinante, O.; Bonoldi, E.; Boracchi, P.; Gatti, C.; Suzuki, H.; Tominaga, T. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst. 1997, 89, 139-147.
34. Linderholm, B.K.; Lindh, B.; Beckman, L.; Erlanson, M.; Edin, K.; Travelin, B.; Bergh, J.; Grankvist, K.; Henriksson, R. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin. Breast Cancer 2003, 4, 340-347.
35. Niedergethmann, M.; Hildenbrand, R.; Wostbrock, B.; Hartel, M.; Sturm, J.W.; Richter, A.; Post, S. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002, 25, 122-129.
36. Kuwahara, K.; Sasaki, T.; Kuwada, Y.; Murakami, M.; Yamasaki, S.; Chayama, K. Expressions of angiogenic factors in pancreatic ductal carcinoma: A correlative study with clinicopathologic parameters and patient survival. Pancreas 2003, 26, 344-349.
37. Kobayashi, A.; Yamaguchi, T.; Ishihara, T.; Ohshima, T.; Baba, T.; Shirai, Y.; Tadenuma, H.; Nakamura, K.; Saisho, H. Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: Differential diagnosis, tumor progression, and patient survival. Pancreas 2005, 31, 74-78.
38. de Vries, C.; Escobedo, J.A.; Ueno, H.; Houck, K.; Ferrara, N.; Williams, L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255, 989-991.
39. Terman, B.I.; Dougher-Vermazen, M.; Carrion, M.E.; Dimitrov, D.; Armellino, D.C.; Gospodarowicz, D.; Bohlen, P. Identification of the kdr tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187, 1579-1586.
40. Barleon, B.; Hauser, S.; Schollmann, C.; Weindel, K.; Marme, D.; Yayon, A.; Weich, H.A. Differential expression of the two vegf receptors flt and kdr in placenta and vascular endothelial cells. J. Cell Biochem. 1994, 54, 56-66.
41. Millauer, B.; Wizigmann-Voos, S.; Schnurch, H.; Martinez, R.; Moller, N.P.; Risau, W.; Ullrich, A. High affinity vegf binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72, 835-846.
42. Matthews, W.; Jordan, C.T.; Gavin, M.; Jenkins, N.A.; Copeland, N.G.; Lemischka, I.R. A receptor tyrosine kinase cdna isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. USA 1991, 88, 9026-9030.
43. von Marschall, Z.; Cramer, T.; Hocker, M.; Burde, R.; Plath, T.; Schirner, M.; Heidenreich, R.; Breier, G.; Riecken, E.O.; Wiedenmann, B.; Rosewicz, S. De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology 2000, 119, 1358-1372.
44. Rooman, I.; Schuit, F.; Bouwens, L. Effect of vascular endothelial growth factor on growth and differentiation of pancreatic ductal epithelium. Lab. Invest. 1997, 76, 225-232.
45. Soker, S.; Takashima, S.; Miao, H.Q.; Neufeld, G.; Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92, 735-745.
46. Soker, S.; Fidder, H.; Neufeld, G.; Klagsbrun, M. Characterization of novel vascular endothelial growth factor (vegf) receptors on tumor cells that bind vegf165 via its exon 7-encoded domain. J. Biol. Chem. 1996, 271, 5761-5767.
47. Gagnon, M.L.; Bielenberg, D.R.; Gechtman, Z.; Miao, H.Q.; Takashima, S.; Soker, S.; Klagsbrun, M. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc. Natl. Acad. Sci. USA 2000, 97, 2573-2578.
48. Wang, L.; Zeng, H.; Wang, P.; Soker, S.; Mukhopadhyay, D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J. Biol. Chem. 2003, 278, 48848-48860.
49. Murga, M.; Fernandez-Capetillo, O.; Tosato, G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 2005, 105, 1992-1999.
50. Pan, Q.; Chanthery, Y.; Liang, W.C.; Stawicki, S.; Mak, J.; Rathore, N.; Tong, R.K.; Kowalski, J.; Yee, S.F.; Pacheco, G.; Ross, S.; Cheng, Z.; Le Couter, J.; Plowman, G.; Peale, F.; Koch, A.W.; Wu, Y.; Bagri, A.; Tessier-Lavigne, M.; Watts, R.J. Blocking neuropilin-1 function has an additive effect with anti-vegf to inhibit tumor growth. Cancer Cell 2007, 11, 53-67.
51. Wang, L.; Mukhopadhyay, D.; Xu, X. C terminus of rgs-gaip-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB J. 2006, 20, 1513-1515.
52. Kitsukawa, T.; Shimono, A.; Kawakami, A.; Kondoh, H.; Fujisawa, H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 1995, 121, 4309-4318.
53. Karkkainen, M.J.; Saaristo, A.; Jussila, L.; Karila, K.A.; Lawrence, E.C.; Pajusola, K.; Bueler, H.; Eichmann, A.; Kauppinen, R.; Kettunen, M.I.; Yla-Herttuala, S.; Finegold, D.N.; Ferrell, R.E.; Alitalo, K. A model for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. USA 2001, 98, 12677-12682.
54. Gluzman-Poltorak, Z.; Cohen, T.; Herzog, Y.; Neufeld, G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms vegf-145 and vegf-165. J. Biol. Chem. 2000, 275, 29922.
55. Fukahi, K.; Fukasawa, M.; Neufeld, G.; Itakura, J.; Korc, M. Aberrant expression of neuropilin-1 and-2 in human pancreatic cancer cells. Clin. Cancer Res. 2004, 10, 581-590.
56. Li, M.; Yang, H.; Chai, H.; Fisher, W.E.; Wang, X.; Brunicardi, F.C.; Yao, Q.; Chen, C. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer 2004, 101, 2341-2350.
57. Baserga, R.; Hongo, A.; Rubini, M.; Prisco, M.; Valentinis, B. The igf-i receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta. 1997, 1332, F105-126.
58. Oyamada, I.; Palka, J.; Schalk, E.M.; Takeda, K.; Peterkofsky, B. Scorbutic and fasted guinea pig sera contain an insulin-like growth factor i-reversible inhibitor of proteoglycan and collagen synthesis in chick embryo chondrocytes and adult human skin fibroblasts. Arch. Biochem. Biophys. 1990, 276, 85-93.
59. Baselga, J.; Norton, L.; Albanell, J.; Kim, Y.M.; Mendelsohn, J. Recombinant humanized antiher2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against her2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998, 58, 2825-2831.
60. Yu, H.; Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. 2000, 92, 1472-1489.
61. Frasca, F.; Pandini, G.; Scalia, P.; Sciacca, L.; Mineo, R.; Costantino, A.; Goldfine, I.D.; Belfiore, A.; Vigneri, R. Insulin receptor isoform a, a newly recognized, high-affinity insulin-like growth factor ii receptor in fetal and cancer cells. Mol. Cell. Biol. 1999, 19, 3278-3288.
62. Remacle-Bonnet, M.; Garrouste, F.; el Atiq, F.; Roccabianca, M.; Marvaldi, J.; Pommier, G. Des-(1-3)-IGF-i, an insulin-like growth factor analog used to mimic a potential IGF-ii autocrine loop, promotes the differentiation of human colon-carcinoma cells. Int. J. Cancer 1992, 52, 910-917.
63. Ma, J.; Pollak, M.N.; Giovannucci, E.; Chan, J.M.; Tao, Y.; Hennekens, C.H.; Stampfer, M.J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-i and igf-binding protein-3. J. Natl. Cancer Inst. 1999, 91, 620-625.
64. Harper, J.; Burns, J.L.; Foulstone, E.J.; Pignatelli, M.; Zaina, S.; Hassan, A.B. Soluble igf2 receptor rescues apc(min/+) intestinal adenoma progression induced by IGF2 loss of imprinting. Cancer Res. 2006, 66, 1940-1948.
65. Ludwig, C.U.; Menke, A.; Adler, G.; Lutz, M.P. Fibroblasts stimulate acinar cell proliferation through igf-i during regeneration from acute pancreatitis. Am. J. Physiol. 1999, 276, G193-G198.
66. Gress, T.M.; Menke, A.; Bachem, M.; Muller-Pillasch, F.; Ellenrieder, V.; Weidenbach, H.; Wagner, M.; Adler, G. Role of extracellular matrix in pancreatic diseases. Digestion 1998, 59, 625-637.
67. Gress, T.M.; Muller-Pillasch, F.; Lerch, M.M.; Friess, H.; Buchler, M.; Beger, H.G.; Adler, G. Balance of expression of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in chronic pancreatitis. Z. Gastroenterol. 1994, 32, 221-225.
68. Gress, T.M.; Muller-Pillasch, F.; Lerch, M.M.; Friess, H.; Buchler, M.; Adler, G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int. J. Cancer 1995, 62, 407-413.
69. Muders, M.H.; Baretton, G.B.; Aust, D.E.; Dutta, S.K.; Wang, E.; Ikeda, Y.; Spaller, M.R.; Datta, K.; Mukhopadhyay, D. GIPC: A new target for therapy in pancreatic adenocarcinoma? Verh. Dtsch. Ges. Pathol. 2007, 91, 286-293.
70. Zeng, H.; Datta, K.; Neid, M.; Li, J.; Parangi, S.; Mukhopadhyay, D. Requirement of different signaling pathways mediated by insulin-like growth factor-i receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem. Biophys. Res. Commun. 2003, 302, 46-55.
71. Ueda, S.; Hatsuse, K.; Tsuda, H.; Ogata, S.; Kawarabayashi, N.; Takigawa, T.; Einama, T.; Morita, D.; Fukatsu, K.; Sugiura, Y.; Matsubara, O.; Mochizuki, H. Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod. Pathol. 2006, 19, 788-796.
72. LaRochelle, W.J.; Jeffers, M.; McDonald, W.F.; Chillakuru, R.A.; Giese, N.A.; Lokker, N.A.; Sullivan, C.; Boldog, F.L.; Yang, M.; Vernet, C.; Burgess, C.E.; Fernandes, E.; Deegler, L.L.; Rittman, B.; Shimkets, J.; Shimkets, R.A.; Rothberg, J.M.; Lichenstein, H.S. PDGF-d, a new protease-activated growth factor. Nat. Cell Biol. 2001, 3, 517-521.
73. Fredriksson, L.; Li, H.; Eriksson, U. The pdgf family: Four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15, 197-204.
74. Reigstad, L.J.; Varhaug, J.E.; Lillehaug, J.R. Structural and functional specificities of pdgf-c and PDGF-d, the novel members of the platelet-derived growth factors family. FEBS J. 2005, 272, 5723-5741.
75. Wang, Z.; Kong, D.; Banerjee, S.; Li, Y.; Adsay, N.V.; Abbruzzese, J.; Sarkar, F.H. Down-regulation of platelet-derived growth factor-d inhibits cell growth and angiogenesis through inactivation of notch-1 and nuclear factor-kappab signaling. Cancer Res. 2007, 67, 11377-11385.
76. Burgess, W.H.; Maciag, T. The heparin-binding (fibroblast) growth factor family of proteins. Annu. Rev. Biochem. 1989, 58, 575-606.
77. Fahmy, R.G.; Dass, C.R.; Sun, L.Q.; Chesterman, C.N.; Khachigian, L.M. Transcription factor EGR-1 supports fgf-dependent angiogenesis during neovascularization and tumor growth. Nat. Med. 2003, 9, 1026-1032.
78. Powers, C.J.; McLeskey, S.W.; Wellstein, A. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 2000, 7, 165-197.
79. Presta, M.; Dell'Era, P.; Mitola, S.; Moroni, E.; Ronca, R.; Rusnati, M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16, 159-178.
80. Thomas-Mudge, R.J.; Okada-Ban, M.; Vandenbroucke, F.; Vincent-Salomon, A.; Girault, J.M.; Thiery, J.P.; Jouanneau, J. Nuclear FGF-2 facilitates cell survival in vitro and during establishment of metastases. Oncogene 2004, 23, 4771-4779.
81. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
82. Friess, H.; Yamanaka, Y.; Buchler, M.; Beger, H.G.; Do, D.A.; Kobrin, M.S.; Korc, M. Increased expression of acidic and basic fibroblast growth factors in chronic pancreatitis. Am. J. Pathol. 1994, 144, 117-128.
83. Lobb, R.R. Clinical applications of heparin-binding growth factors. Eur. J. Clin. Invest. 1988, 18, 321-336.
84. Yamanaka, Y.; Friess, H.; Buchler, M.; Beger, H.G.; Uchida, E.; Onda, M.; Kobrin, M.S.; Korc, M. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 1993, 53, 5289-5296.
85. Pardo, O.E.; Lesay, A.; Arcaro, A.; Lopes, R.; Ng, B.L.; Warne, P.H.; McNeish, I.A.; Tetley, T.D.; Lemoine, N.R.; Mehmet, H.; Seckl, M.J.; Downward, J. Fibroblast growth factor 2-mediated translational control of iaps blocks mitochondrial release of smac/diablo and apoptosis in small cell lung cancer cells. Mol. Cell. Biol. 2003, 23, 7600-7610.
86. Brattstrom, D.; Bergqvist, M.; Hesselius, P.; Larsson, A.; Lamberg, K.; Wernlund, J.; Brodin, O.; Wagenius, G. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002, 37, 57-63.
87. Udayakumar, T.S.; Nagle, R.B.; Bowden, G.T. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line. Prostate 2004, 58, 66-75.
88. Liu, B.; Fang, M.; Lu, Y.; Mendelsohn, J.; Fan, Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and g1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 2001, 20, 1913-1922.
89. Jayson, G.C.; Gallagher, J.T. Heparin oligosaccharides: Inhibitors of the biological activity of bfgf on CACO-2 cells. Br. J. Cancer 1997, 75, 9-16.
90. Tassi, E.; Henke, R.T.; Bowden, E.T.; Swift, M.R.; Kodack, D.P.; Kuo, A.H.; Maitra, A.; Wellstein, A. Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon. Cancer Res. 2006, 66, 1191-1198.
91. Johnson, D.E.; Lee, P.L.; Lu, J.; Williams, L.T. Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol. Cell. Biol. 1990, 10, 4728-4736.
92. Jaye, M.; Schlessinger, J.; Dionne, C.A. Fibroblast growth factor receptor tyrosine kinases: Molecular analysis and signal transduction. Biochim. Biophys. Acta 1992, 1135, 185-199.
93. Mignatti, P.; Tsuboi, R.; Robbins, E.; Rifkin, D.B. In vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor-induced proteinases. J. Cell Biol. 1989, 108, 671-682.
94. Moscatelli, D.; Presta, M.; Rifkin, D.B. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proc. Natl. Acad. Sci. USA 1986, 83, 2091-2095.
95. Montesano, R.; Vassalli, J.D.; Baird, A.; Guillemin, R.; Orci, L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. USA 1986, 83, 7297-7301.
96. Korc, M.; Friess, H.; Yamanaka, Y.; Kobrin, M.S.; Buchler, M.; Beger, H.G. Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase c gamma. Gut 1994, 35, 1468-1473.
97. Friess, H.; Yamanaka, Y.; Kobrin, M.S.; Do, D.A.; Buchler, M.W.; Korc, M. Enhanced ERBB-3 expression in human pancreatic cancer correlates with tumor progression. Clin. Cancer Res. 1995, 1, 1413-1420.
98. Bergmann, F.; Aulmann, S.; Wente, M.N.; Penzel, R.; Esposito, I.; Kleeff, J.; Friess, H.; Schirmacher, P. Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J. Clin. Pathol. 2006, 59, 580-584.
99. Kazbay, K.; Tarnasky, P.R.; Hawes, R.H.; Cotton, P.B. Increased transforming growth factor beta in pure pancreatic juice in pancreatitis. Pancreas 2001, 22, 193-195.
100. Markowitz, S.D.; Roberts, A.B. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 1996, 7, 93-102.
101. Apte, M.V.; Wilson, J.S. Mechanisms of pancreatic fibrosis. Dig Dis 2004, 22, 273-279.
102. Shek, F.W.; Benyon, R.C.; Walker, F.M.; McCrudden, P.R.; Pender, S.L.; Williams, E.J.; Johnson, P.A.; Johnson, C.D.; Bateman, A.C.; Fine, D.R.; Iredale, J.P. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am. J. Pathol. 2002, 160, 1787-1798.
103. Saotome, T.; Inoue, H.; Fujimiya, M.; Fujiyama, Y.; Bamba, T. Morphological and immunocytochemical identification of periacinar fibroblast-like cells derived from human pancreatic acini. Pancreas 1997, 14, 373-382.
104. Vogelmann, R.; Ruf, D.; Wagner, M.; Adler, G.; Menke, A. Effects of fibrogenic mediators on the development of pancreatic fibrosis in a tgf-beta1 transgenic mouse model. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280, G164-G172.
105. Yamamoto, M.; Otani, M.; Otsuki, M. A new model of chronic pancreatitis in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291, G700-G708.
106. Haber, P.S.; Keogh, G.W.; Apte, M.V.; Moran, C.S.; Stewart, N.L.; Crawford, D.H.; Pirola, R.C.; McCaughan, G.W.; Ramm, G.A.; Wilson, J.S. Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. Am. J. Pathol. 1999, 155, 1087-1095.
107. di Mola, F.F.; Friess, H.; Martignoni, M.E.; Di Sebastiano, P.; Zimmermann, A.; Innocenti, P.; Graber, H.; Gold, L.I.; Korc, M.; Buchler, M.W. Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann. Surg. 1999, 230, 63-71.
108. Fukumura, Y.; Kumasaka, T.; Mitani, K.; Karita, K.; Suda, K. Expression of transforming growth factor beta1, beta2, and beta3 in chronic, cancer-associated, obstructive pancreatitis. Arch. Pathol. Lab. Med. 2006, 130, 356-361.
109. Halvorsen, T.B.; Seim, E. Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. J. Clin. Pathol. 1989, 42, 162-166.
110. Barsky, S.H.; Gopalakrishna, R. Increased invasion and spontaneous metastasis of bl6 melanoma with inhibition of the desmoplastic response in c57 bl/6 mice. Cancer Res. 1987, 47, 1663-1667.
111. Satoh, K.; Shimosegawa, T.; Hirota, M.; Koizumi, M.; Toyota, T. Expression of transforming growth factor beta1 (TGF beta1) and its receptors in pancreatic duct cell carcinoma and in chronic pancreatitis. Pancreas 1998, 16, 468-474.
112. Ammann, R.W.; Akovbiantz, A.; Largiader, F.; Schueler, G. Course and outcome of chronic pancreatitis. Longitudinal study of a mixed medical-surgical series of 245 patients. Gastroenterology 1984, 86, 820-828.
113. Ammann, R.W.; Muellhaupt, B. The natural history of pain in alcoholic chronic pancreatitis. Gastroenterology 1999, 116, 1132-1140.
114. Andren-Sandberg, A.; Dervenis, C.; Lowenfels, B. Etiologic links between chronic pancreatitis and pancreatic cancer. Scand. J. Gastroenterol. 1997, 32, 97-103.
115. Steer, M.L.; Meldolesi, J. Pathogenesis of acute pancreatitis. Annu. Rev. Med. 1988, 39, 95-105.
116. Steer, M.L. Classification and pathogenesis of pancreatitis. Surg. Clin. North Am. 1989, 69, 467-480.
117. Bank, S.; Indaram, A. Causes of acute and recurrent pancreatitis. Clinical considerations and clues to diagnosis. Gastroenterol. Clin. North Am. 1999, 28, 571-589, viii.
118. Ammann, R.W. A clinically based classification system for alcoholic chronic pancreatitis: Summary of an international workshop on chronic pancreatitis. Pancreas 1997, 14, 215-221.
119. Lerch, M.M.; Saluja, A.K.; Dawra, R.; Ramarao, P.; Saluja, M.; Steer, M.L. Acute necrotizing pancreatitis in the opossum: Earliest morphological changes involve acinar cells. Gastroenterology 1992, 103, 205-213.
120. Busing, M.; Hopt, U.T.; Quacken, M.; Becker, H.D.; Morgenroth, K. Morphological studies of graft pancreatitis following pancreas transplantation. Br. J. Surg. 1993, 80, 1170-1173.
121. Busing, M.; Hopt, U.; Quacken, M.; Becker, H.; Morgenroth, K. Morphological studies of graft pancreatitis following pancreas transplantation. Br. J. Surg. 1993, 80, 1170-1174.
122. Kusterer, K.; Poschmann, T.; Friedemann, A.; Enghofer, M.; Zendler, S.; Usadel, K.H. Arterial constriction, ischemia-reperfusion, and leukocyte adherence in acute pancreatitis. Am. J. Physiol. 1993, 265, G165-G171.
123. Pezzilli, R.; Billi, P.; Beltrandi, E.; Casadei Maldini, M.; Mancini, R. Impaired lymphocyte proliferation in human acute pancreatitis. Digestion 1997, 58, 431-436.
124. Menke, A.; Geerling, I.; Giehl, K.; Vogelmann, R.; Reinshagen, M.; Adler, G. Transforming growth factor-beta-induced upregulation of transforming growth factor-beta receptor expression in pancreatic regeneration. Biochim. Biophys. Acta. 1999, 1449, 178-185.
125. Casini, A.; Galli, A.; Pignalosa, P.; Frulloni, L.; Grappone, C.; Milani, S.; Pederzoli, P.; Cavallini, G.; Surrenti, C. Collagen type i synthesized by pancreatic periacinar stellate cells (PSC) co-localizes with lipid peroxidation-derived aldehydes in chronic alcoholic pancreatitis. J. Pathol. 2000, 192, 81-89.
126. Comfort, M.W.; Gambrill, E.E.; Baggenstoss, A.H. Chronic relapsing pancreatitis. A study of twenty-nine cases without associated disease of the biliary or gastro-intestinal tract. Gastroenterology 1968, 54 (Suppl. 7), 60-765.
127. Etemad, B.; Whitcomb, D.C. Chronic pancreatitis: Diagnosis, classification, and new genetic developments. Gastroenterology 2001, 120, 682-707.
128. Lee, M.S.; Gu, D.; Feng, L.; Curriden, S.; Arnush, M.; Krahl, T.; Gurushanthaiah, D.; Wilson, C.; Loskutoff, D.L.; Fox, H.; et al. Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-beta 1. Am. J. Pathol. 1995, 147, 42-52.
129. Neuschwander-Tetri, B.A.; Burton, F.R.; Presti, M.E.; Britton, R.S.; Janney, C.G.; Garvin, P.R.; Brunt, E.M.; Galvin, N.J.; Poulos, J.E. Repetitive self-limited acute pancreatitis induces pancreatic fibrogenesis in the mouse. Dig Dis Sci. 2000, 45, 665-674.
130. Esposito, I.; Friess, H.; Buchler, M.W. Molecular mechanisms in chronic pancreatitis. Zentralbl Chir 2001, 126, 867-872.
131. Kobrin, M.S.; Yamanaka, Y.; Friess, H.; Lopez, M.E.; Korc, M. Aberrant expression of type i fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res. 1993, 53, 4741-4744.
132. Lowenfels, A.B.; Maisonneuve, P.; Cavallini, G.; Ammann, R.W.; Lankisch, P.G.; Andersen, J.R.; Dimagno, E.P.; Andren-Sandberg, A.; Domellof, L. Pancreatitis and the risk of pancreatic cancer. International pancreatitis study group. N. Engl. J. Med. 1993, 328, 1433-1437.
133. Bansal, P.; Sonnenberg, A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995, 109, 247-251.
134. Wynder, E.L.; Mabuchi, K.; Maruchi, N.; Fortner, J.G. Epidemiology of cancer of the pancreas. J. Natl. Cancer Inst. 1973, 50, 645-667.
135. Esposito, I.; Menicagli, M.; Funel, N.; Bergmann, F.; Boggi, U.; Mosca, F.; Bevilacqua, G.; Campani, D. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J. Clin. Pathol. 2004, 57, 630-636.
136. Dite, P.; Pazourkova, M.; Ruzicka, M.; Precechtelova, M.; Novotny, I.; Dastych, M. Chronic pancreatitis as a risk factor for pancreatic carcinoma. Vnitr Lek 2002, 48, 638-641.
137. Appel, M.F. Hereditary pancreatitis. Review and presentation of an additional kindred. Arch. Surg. 1974, 108, 63-65.
138. Kleeff, J.; Kusama, T.; Rossi, D.L.; Ishiwata, T.; Maruyama, H.; Friess, H.; Buchler, M.W.; Zlotnik, A.; Korc, M. Detection and localization of MIP-3alpha/LARC/EXODUS, a macrophage proinflammatory chemokine, and its ccr6 receptor in human pancreatic cancer. Int. J. Cancer 1999, 81, 650-657.
139. Ectors, N.; Maillet, B.; Aerts, R.; Geboes, K.; Donner, A.; Borchard, F.; Lankisch, P.; Stolte, M.; Luttges, J.; Kremer, B.; Kloppel, G. Non-alcoholic duct destructive chronic pancreatitis. Gut 1997, 41, 263-268.
140. Smith, M.P.; Loe, R.H. Sclerosing cholangitis; review of recent case reports and associated diseases and four new cases. Am. J. Surg. 1965, 110, 239-246.
141. Waldram, R.; Kopelman, H.; Tsantoulas, D.; Williams, R. Chronic pancreatitis, sclerosing cholangitis, and sicca complex in two siblings. Lancet 1975, 1, 550-552.
142. Hahm, K.B.; Im, Y.H.; Lee, C.; Parks, W.T.; Bang, Y.J.; Green, J.E.; Kim, S.J. Loss of tgf-beta signaling contributes to autoimmune pancreatitis. J. Clin. Invest. 2000, 105, 1057-1065.
143. Histological typing of tumours of the exocrine pancreas. In Who International Histological Classification of Tumours; 2nd ed.; Kloppel, G.S.E., Longnecker, D., Capella, C., Sobin, L.H., Eds.; Springer-Verlag: Berlin, Gemany, 1996.
144. Sarles, H.; Martin, M.; Camatte, R.; Sarles, J.C. The separation of the pancreatites: The pseudocysts of acute pancreatitis and of chronic pancreatitis. Presse Med. 1963, 71, 237-240.
145. Grace, P.A.; Williamson, R.C. Modern management of pancreatic pseudocysts. Br. J. Surg. 1993, 80, 573-581.
146. Garcea, G.; Ong, S.L.; Rajesh, A.; Neal, C.P.; Pollard, C.A.; Berry, D.P.; Dennison, A.R. Cystic lesions of the pancreas. A diagnostic and management dilemma. Pancreatology 2008, 8, 236-251.
147. Safioleas, M.C.; Moulakakis, K.G.; Manti, C.; Kostakis, A. Clinical considerations of primary hydatid disease of the pancreas. Pancreatology 2005, 5, 457-461.
148. Adsay, N.V.; Longnecker, D.S.; Klimstra, D.S. Pancreatic tumors with cystic dilatation of the ducts: Intraductal papillary mucinous neoplasms and intraductal oncocytic papillary neoplasms. Semin. Diagn. Pathol. 2000, 17, 16-30.
149. Kloppel, G. Pseudocysts and other non-neoplastic cysts of the pancreas. Semin. Diagn. Pathol. 2000, 17, 7-15.
150. Yang, J.M.; Lee, J.; Southern, J.F.; Warshaw, A.L.; Dhanak, E.; Lewandrowski, K.B. Measurement of ps2 protein in pancreatic cyst fluids. Evidence for a potential role of ps2 protein in the pathogenesis of mucinous cystic tumors. Int. J. Pancreatol. 1998, 24, 181-186.
151. Andreoni, B.; Biffi, R.; Marzona, L.; Pozzi, S.; Lotti, M.; Luca, F. Feasibility of exeresis. Controversial aspects in the surgery of carcinoma of the pancreas. Ann. Ital. Chir. 1997, 68, 591-594.
152. Friess, H.; Isenmann, R.; Berberat, P.; Kleeff, J.; Buchler, M.W. Prognosis in pancreatic carcinoma. Ther. Umsch. 1996, 53, 401-407.
153. Tomaszewska, R. Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma. Folia Med. Cracov. 1999, 40, 101-141.
154. Coppola, D. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000, 7, 421-427.
155. Bardeesy, N.; DePinho, R.A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2002, 2, 897-909.
156. Douglass, H.O. Current approaches to multimodality management of advanced pancreatic cancer. Hepatogastroenterology 1993, 40, 433-442.
157. Morohoshi, T.; Held, G.; Kloppel, G. Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology 1983, 7, 645-661.
158. Kleeff, J.; Michalski, C.; Friess, H.; Buchler, M.W. Pancreatic cancer: From bench to 5-year survival. Pancreas 2006, 33, 111-118.
159. Torrisani, J.; Bournet, B.; Cordelier, P.; Buscail, L. New molecular targets in pancreatic cancer. Bull. Cancer 2008, 95, 503-512.
160. Buscail, L.; Bournet, B. Risk factors of pancreatic carcinoma. Presse Med. 2007, 36, 1244-1248.
161. Shimizu, K.; Kobayashi, M.; Tahara, J.; Shiratori, K. Cytokines and peroxisome proliferator-activated receptor gamma ligand regulate phagocytosis by pancreatic stellate cells. Gastroenterology 2005, 128, 2105-2118.
162. Dembinski, A.; Warzecha, Z.; Ceranowicz, P.; Dembinski, M.; Cieszkowski, J.; Pawlik, W.W.; Tomaszewska, R.; Konturek, S.J.; Konturek, P.C. Effect of ischemic preconditioning on pancreatic regeneration and pancreatic expression of vascular endothelial growth factor and platelet-derived growth factor-a in ischemia/reperfusion-induced pancreatitis. J. Physiol. Pharmacol. 2006, 57, 39-58.
163. Warzecha, Z.; Dembinski, A.; Ceranowicz, P.; Dembinski, M.; Kownacki, P.; Konturek, S.J.; Tomaszewska, R.; Stachura, J.; Hladki, W.; Pawlik, W.W. Immunohistochemical expression of FGF-2, PDGF-a, VEGF and TGF beta rii in the pancreas in the course of ischemia/reperfusioninduced acute pancreatitis. J. Physiol. Pharmacol. 2004, 55, 791-810.
164. Jiang, X.; Abiatari, I.; Kong, B.; Erkan, M.; De Oliveira, T.; Giese, N.A.; Michalski, C.W.; Friess, H.; Kleeff, J. Pancreatic islet and stellate cells are the main sources of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 in pancreatic cancer. Pancreatology 2008, 9, 165-172.
165. Neid, M.; Datta, K.; Stephan, S.; Khanna, I.; Pal, S.; Shaw, L.; White, M.; Mukhopadhyay, D. Role of insulin receptor substrates and protein kinase c-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J. Biol. Chem. 2004, 279, 3941-3948.
166. Stoeltzing, O.; Liu, W.; Reinmuth, N.; Fan, F.; Parikh, A.A.; Bucana, C.D.; Evans, D.B.; Semenza, G.L.; Ellis, L.M. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-i receptor autocrine loop in human pancreatic cancer. Am. J. Pathol. 2003, 163, 1001-1011.
167. Baker, C.H.; Solorzano, C.C.; Fidler, I.J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 2002, 62, 1996-2003.
168. Parikh, A.A.; Liu, W.B.; Fan, F.; Stoeltzing, O.; Reinmuth, N.; Bruns, C.J.; Bucana, C.D.; Evans, D.B.; Ellis, L.M. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 2003, 98, 720-729.
169. Yan, C.Q.; Zhao, Y.P.; Dai, M.H.; Song, Y.M.; Wu, Y.D. The relationship between the changes of proangiogenic factors serum concentrations and progression of pancreatic carcinoma patients. Zhonghua Wai Ke Za Zhi 2007, 45, 496-498.
170. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; Marshak, D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, 143-147.
171. Beckermann, B.M.; Kallifatidis, G.; Groth, A.; Frommhold, D.; Apel, A.; Mattern, J.; Salnikov, A.V.; Moldenhauer, G.; Wagner, W.; Diehlmann, A.; Saffrich, R.; Schubert, M.; Ho, A.D.; Giese, N.; Buchler, M.W.; Friess, H.; Buchler, P.; Herr, I. Vegf expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br. J. Cancer 2008, 99, 622-631.
172. Korc, M. Pancreatic cancer-associated stroma production. Am. J. Surg. 2007, 194, S84-S86.
173. Studeny, M.; Marini, F.C.; Champlin, R.E.; Zompetta, C.; Fidler, I.J.; Andreeff, M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002, 62, 3603-3608.
174. Oka, M.; Iwata, C.; Suzuki, H.I.; Kiyono, K.; Morishita, Y.; Watabe, T.; Komuro, A.; Kano, M.R.; Miyazono, K. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood 2008, 111, 4571-4579.
175. Teraoka, H.; Sawada, T.; Nishihara, T.; Yashiro, M.; Ohira, M.; Ishikawa, T.; Nishino, H.; Hirakawa, K. Enhanced vegf production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br. J. Cancer 2001, 85, 612-617.
176. Smirne, C.; Camandona, M.; Alabiso, O.; Bellone, G.; Emanuelli, G. High serum levels of transforming growth factor-beta1, interleukin-10 and vascular endothelial growth factor in pancreatic adenocarcinoma patients. Minerva Gastroenterol Dietol 1999, 45, 21-27.
177. Sako, A.; Kitayama, J.; Yamaguchi, H.; Kaisaki, S.; Suzuki, H.; Fukatsu, K.; Fujii, S.; Nagawa, H. Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: Possible role of mesothelial cell on the development of peritoneal metastasis. J. Surg. Res. 2003, 115, 113-120.
178. Compagni, A.; Wilgenbus, P.; Impagnatiello, M.A.; Cotten, M.; Christofori, G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 2000, 60, 7163-7169.
179. Niu, J.; Chang, Z.; Peng, B.; Xia, Q.; Lu, W.; Huang, P.; Tsao, M.S.; Chiao, P.J. Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of nf-kappab transcription factors. J. Biol. Chem. 2007, 282, 6001-6011.
180. Muerkoster, S.; Wegehenkel, K.; Arlt, A.; Witt, M.; Sipos, B.; Kruse, M.L.; Sebens, T.; Kloppel, G.; Kalthoff, H.; Folsch, U.R.; Schafer, H. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 2004, 64, 1331-1337.
181. Schneider, E.; Schmid-Kotsas, A.; Zhao, J.; Weidenbach, H.; Schmid, R.M.; Menke, A.; Adler, G.; Waltenberger, J.; Grunert, A.; Bachem, M.G. Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells. Am. J. Physiol. Cell Physiol. 2001, 281, C532-C543.